Table 2
Factors affecting the 6-month functional response to ChEI treatment (final general linear models)
Dependent variable, change from baseline IADL PSMS
Percentage of variance accounted for R2= 0.310,p< 0.001 R2= 0.335,p< 0.001
Significant predictors β 95% CI (β) pvalue β 95% CI (β) pvalue
Intercept −10.922 −15.585, –6.259 < 0.001 0.419 −2.156, 2.995 0.749
Age at first assessment, years −0.041 −0.070, –0.011 0.007 −0.018 −0.036, –0.001 0.036
ADL score at baselinea 0.521 0.300, 0.741 < 0.001 −0.175 −0.441, 0.090 0.196
MMSE score at baseline 0.453 0.267, 0.640 < 0.001 −0.021 −0.128, 0.086 0.697
Number of medications at baseline ns −0.079 −0.134, –0.024 0.005
NSAIDs/Acetylsalicylic acid (no = 0, yes = 1) ns 0.419 0.133, 0.705 0.004
Interaction terms:
ADL baseline scorea × MMSE baseline score −0.016 −0.026, –0.006 0.002 0.018 0.005, 0.032 0.008

Gender, APOE ε4 carrier status, solitary living, age at onset (or duration of AD), years of education and the variables comparing the ChEI agents and dose were not significant.

β values are expressed per 1 unit increase for continuous variables and for the condition present in dichotomous variables

aADL = IADL or PSMS, respectively.

ChEI cholinesterase inhibitor, CI confidence interval, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drugs, ns not significant, PSMS Physical Self-Maintenance Scale.

Wattmo et al. BMC Neurology 2012 12:134   doi:10.1186/1471-2377-12-134

Open Data